Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib/ HRS-1167, Famitinib and Camrelizumab: A Prospective, Open-label, Multicenter, Phase II Trial

This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy. The characteristics of this study are a precision treatment scheme without chemotherapy, the scheme of HRS-1167 combined with famitinib neoadjuvant therapy for patients with gBRCA mutations is explored, and the efficacy of combined immunotherapy is further explored according to the efficacy of the combination of the two drugs.

Study Overview

• Status: Recruiting
• Conditions: HER2-negative Breast Cancer; BRCA-Mutated Breast Carcinoma
• Intervention / Treatment: Drug: HRS-1167; Drug: Famitinib; Drug: Camrelizumab

Detailed Description

This study is a prospective, open-label, multi-center, phase II clinical trial designed for HER2-negative breast cancer with pathogenic mutations in the germline gene (gBRCA1/2) that were indicated for neoadjuvant chemotherapy. The characteristics of this study are a precision treatment scheme without chemotherapy, the scheme of HRS-1167 combined with famitinib neoadjuvant therapy for patients with gBRCA mutations is explored, and the efficacy of combined immunotherapy is further explored according to the efficacy of the combination of the two drugs. The study consists of a safety run-in period to explore the safety of HRS-1167 combined with famitinib, which is used to provide a recommended dose for the combination of HRS-1167 and famitinib. The latter phase II period is used to explore the efficacy of HRS-1167 plus famitinib /HRS-1167 plus famitinib plus camrelizumab as neoadjuvant therapy for gBRCA-mutated HER2-negative breast cancer. The primary endpoints in safety run-in period: the incidence of dose-limiting toxicity (DLT), the incidence and severity of adverse events (AE) and serious adverse events (SAE) ; in phase 2: the rate of pathological complete response (pCR) after surgery for each cohort as assessed by the investigator. Secondary endpoints included residual cancer burden (RCB) score, 3-year event-free survival (EFS), objective response rate (ORR), complete cell cycle arrest (CCCA) rate for HR+/HER2 - breast cancer, safety, and translational exploration study.

• Study Type: Interventional
• Enrollment (Estimated): 130
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Zhi-Ming Shao, MD; Phone Number: 86-21-641755901105; Email: zhimingshao@yahoo.com
• Study Contact Backup: Name: Xi-Yu Liu, MD; Phone Number: 86-21-64175590-63202; Email: liu-xiyu@163.com

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200032
      • Recruiting
      • Breast cancer institute of Fudan University Cancer Hospital
      • Contact: Zhi-Ming Shao, MD; Phone Number: 86-21-641755901105; Email: zhimingshao@yahoo.com
      • Principal Investigator: Zhi-Ming Shao, MD
      • Contact: Junjie Li, MD; Phone Number: 86-21-64175590; Email: lijunjie_ronaldo@hotmail.com
      • Sub-Investigator: Junjie Li, MD
      • Sub-Investigator: Xi-Yu Liu, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age 18 to 70 years old, female.
2. Patients with histologically confirmed unilateral primary invasive breast cancer who meet the criteria of cT0-4, N1-3, M0 or cT≥3, N0, M0 (inflammatory breast cancer not included).
3. Patients with HER-2 negative disease. HER2-negative disease was defined as follows: disease whose HER-2 is 1+ or negative by immunohistochemical (IHC), or fluorescence in situ hybridization (FISH) is negative if IHC is 2+.
4. Patients with pathogenic germline BRCA 1/2 mutation.
5. According to the RECIST 1.1 criteria, there is at least one measurable objective lesion.
6. Eastern Cooperative Oncology Group (ECOG) performance score 0-1.
7. Appropriate haematological, hepatic and renal function (no blood transfusion or hematopoietic stimulating factors within 14 days): 1) Absolute number of neutrophils (ANC) ≥ 1.5 x 10^9/L; 2) Platelets ≥ 100 x 10^9/L; 3) Hemoglobin ≥ 90 g/L ; 4) White blood cell (WBC) ≥ 3.0×10^9/L and ≤15×10^9/L; 5) Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); 6) AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN; 7) serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance (CrCL) ≥50 mL/min (Cockcroft-Gault equation); 8) Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 ULN with international normalized ratio (INR) ≤1.5 ULN (not receiving anticoagulation); 9) Serum albumin ≥ 2.5g/dL.
8. Left ventricular ejection fraction (LVEF) ≥ 50%.
9. 12-lead ECG: QT interval corrected by Fridericia method (QTcF) < 470 msec.
10. Urine test: urinary protein < 2+; If urinary protein ≥ 2+, 24-hour urinary protein quantification must show protein ≤1g.
11. Subject is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
12. With good compliance with the planned treatment, are able to understand the follow-up procedures of this study and sigh the informed consent form.

Exclusion Criteria:

Patients with any of the following were not enrolled in the study:

1. Cancer-related history and treatment history: 1) Bilateral breast cancer; 2) Previous history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS); 3) Previous history of invasive or metastatic breast cancer; 4) Any malignant tumor was diagnosed within 3 years before signing the informed consent, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma; 5) Received systemic chemotherapy, systemic targeted therapy and local radiotherapy within 3 years before signing the informed consent; 6) Previously treated with VEGFR small molecule tyrosine kinase inhibitors (such as famitinib, sorafenib, sunitinib, regorafenib, etc.) (except bevacizumab); 7) Prior treatment with PARP inhibitors for any disease;
2. Stage IV breast cancer according to the AJCC staging system, 8th edition.
3. Inflammatory breast cancer or breast rupture.
4. There are clinical symptoms or diseases of the heart that are not well controlled
5. Hypertension that is not well controlled by antihypertensive medication: systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 90 mmHg has a history of hypertensive crisis or hypertensive encephalopathy.
6. NCI-CTCAE v5.0 grade ≥2 bleeding events occurred within 4 weeks before the first medication, including but not limited to hemoptysis (single episode of hemoptysis volume ≥ 2mL), vaginal bleeding, gastrointestinal bleeding, etc.
7. Excessive arterial/venous thrombosis events occurred within 6 months before the first medication, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc. Patients with lower extremity intermuscular venous thrombosis who were evaluated as not requiring anticoagulant therapy, and those whose mural thrombus caused by catheterization had disappeared and did not require drug therapy were considered for enrollment.
8. Inability to swallow tablets normally or abnormal gastrointestinal function, which may affect drug absorption as judged by the researcher;
9. Receipt of a strong inhibitor of CYP3A4, CYP2D6, P-gp, or BCRP from the date of first dose <5 times of drug half-lives or 14 days; The interval between receiving treatment with the above enzyme strong inducers and the first dose < 28 days.
10. Evidence of any disease as judged by the investigator (e.g., severe or uncontrolled systemic disease, including severe systemic infection, uncontrolled hypertension, renal transplantation and active bleeding disease, coagulation disorders, platelet dysfunction, severe chronic gastrointestinal disease, or patients with other serious medical conditions);
11. Have undergone major surgery other than invasive diagnostic procedures, peripherally inserted central catheter (PICC) procedures, or pathological biopsy within 28 days prior to the first dose, or are expected to undergo major surgery during the study period;
12. Unhealed wounds, ulcers, or fractures;
13. Active hepatitis B (defined as hepatitis B surface antigen [HBsAg] positive and HBV-DNA ≥500IU/ml);
14. Hepatitis C infection (defined as a positive test for hepatitis C virus antibody [HCV-Ab] and an HCV-RNA test higher than the lower limit of the assay);
15. Known history of human immunodeficiency virus (HIV) infection;
16. Known history of psychotropic substance abuse, alcohol or drug abuse;
17. Active psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, etc.) and depression being treated with antidepressants were not exclusion criteria.
18. Patients with known allergy or intolerance to the study drug or its excipents;
19. Patients of reproductive age who are pregnant or lactating, and who refuse to use appropriate contraception during the course of the trial;
20. Participated in other trial studies within 30 days before the first dose of the study drug, or not more than 5 half-lives since the last dose of the study drug;
21. Patients judged by the investigator to be ineligible for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Safety run-in; HRS-1167 + famitinib	Drug: HRS-1167; a highly selective PARP1 inhibitor; Drug: Famitinib; a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
Experimental: Phase 2: Cohort A (HR+/HER2-, gBRCAm); HRS-1167 + famitinib, RP2D	Drug: HRS-1167; a highly selective PARP1 inhibitor; Drug: Famitinib; a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
Experimental: Phase 2: Cohort B (HR-/HER2-, gBRCAm); HRS-1167 + famitinib, RP2D	Drug: HRS-1167; a highly selective PARP1 inhibitor; Drug: Famitinib; a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
Experimental: Phase 2: Cohort C (HR+/HER2-, gBRCAm expansion cohort); HRS-1167 + famitinib, (RP2D) + camrelizumab	Drug: HRS-1167; a highly selective PARP1 inhibitor; Drug: Famitinib; a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit; Drug: Camrelizumab; a humanised anti-programmed death-1 (anti PD-1) antibody
Experimental: Phase 2: Cohort D (HR-/HER2-, gBRCAm expansion cohort); HRS-1167 + famitinib, (RP2D) + camrelizumab	Drug: HRS-1167; a highly selective PARP1 inhibitor; Drug: Famitinib; a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit; Drug: Camrelizumab; a humanised anti-programmed death-1 (anti PD-1) antibody

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety run-in: Incidence rate of dose-limiting toxicities (DLTs)	Incidence rate of DLT will be evaluated in participants in the Safety Run-In, who will be followed for protocol-defined DLT events up to 28±3 days after the first dose of HRS-1167 and famitinib.	28±3 days
Safety run-in: adverse events (AEs)	Incidence rate of AEs of any cause will be evaluated in participants in the Safety Run-In according to CTCAE v5.0.	28±3 days
Safety run-in: Serious adverse events (SAEs)	Incidence rate of SAEs of any cause will be evaluated in participants in the Safety Run-In according to CTCAE v5.0.	28±3 days
Phase 2: Total Pathologic complete response (tpCR: ypT0/Tis ypN0) rate	Defined as no residual invasive cancer cells are found in the pathological examination of breast and axillary lymph node; if only residual in situ cancer cells are present in the surgical specimens, it can also be considered as achieving a pathological complete response.	Immediately after the surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase 2: Residual Cancer Burden (RCB)	RCB will be estimated from routine pathological sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. The pathological variables include bidimensional diameters of the primary tumor bed, the proportion of primary tumor area containing invasive carcinoma, the number of positive lymph nodes, and the diameter of the largest nodal metastasis	Immediately after the surgery
Phase 2: Event-free survival (EFS)	Defined as the time from the date of the first study dose to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause.	Approximately 3 years
Phase 2: Objective response rate (ORR)	Defined as the proportion of patients with complete response (CR) and partial response (PR) by magnetic resonance imaging (MRI) according to RECIST v1.1.	Immediately after the surgery
Phase 2: Rate of complete cell cycle arrest (CCCA) in HR+/HER2- breast cancer	Rate of CCCA determined by IHC Ki67 ( Ki67 ≤ 2.7%) between pre- and post-treatment.	After 4 weeks of therapy
Phase 2: Adverse events (AEs)	Incidence rate of AEs of any cause will be evaluated in participants enrolled in the phase 2 period according to CTCAE v5.0.	Up to 6 months
Phase 2: Serious adverse events (SAEs)	Incidence rate of SAEs of any cause will be evaluated in participants enrolled in the phase 2 period according to CTCAE v5.0.	Up to 6 months
Biomarker analysis1	Gene mutations in the paired tumor and peripheral blood will be tested and analysed to predict therapy response.	At baseline, at the end of first 2 cycles (each cycle is 28 days) and immediately after the surgery
Biomarker analysis 2	Gene expression signatures in the paired tumor and peripheral blood will be tested and analysed to predict therapy response.	At baseline, at the end of first 2 cycles (each cycle is 28 days) and immediately after the surgery

Collaborators and Investigators

• Sponsor: Fudan University
• Investigators: Principal Investigator: Zhi-Ming Shao, MD, Fudan University

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2024
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2027

Study Registration Dates

• First Submitted: July 1, 2024
• First Submitted That Met QC Criteria: July 18, 2024
• First Posted (Actual): July 23, 2024

Study Record Updates

• Last Update Posted (Estimated): December 12, 2024
• Last Update Submitted That Met QC Criteria: December 9, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: SCHBCC-N074

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No